268 related articles for article (PubMed ID: 33155948)
1. [Combined Lipid-Lowering Therapy in Elderly and Senile Patients].
Shaposhnik II; Genkel VV; Salashenko AO
Kardiologiia; 2020 Aug; 60(7):103-107. PubMed ID: 33155948
[TBL] [Abstract][Full Text] [Related]
2. IMPROVE-IT clinical implications. Should the "high-intensity cholesterol-lowering therapy" strategy replace the "high-intensity statin therapy"?
Masana L; Pedro-Botet J; Civeira F
Atherosclerosis; 2015 May; 240(1):161-2. PubMed ID: 25795557
[No Abstract] [Full Text] [Related]
3. Statin combination therapy and cardiovascular risk reduction.
Toth PP; Farnier M; Tomassini JE; Foody JM; Tershakovec AM
Future Cardiol; 2016 May; 12(3):289-315. PubMed ID: 27079178
[TBL] [Abstract][Full Text] [Related]
4. A Bayesian network meta-analysis of PCSK9 inhibitors, statins and ezetimibe with or without statins for cardiovascular outcomes.
Khan SU; Talluri S; Riaz H; Rahman H; Nasir F; Bin Riaz I; Sattur S; Ahmed H; Kaluski E; Krasuski R
Eur J Prev Cardiol; 2018 May; 25(8):844-853. PubMed ID: 29569492
[TBL] [Abstract][Full Text] [Related]
5. [ACUTE CORONARY SYNDROME AND LIPID-LOWERING THERAPY. DOES THE IMPROVE-IT STUDY MAKE ANY DIFFERENCE?].
Lancellotti P; Pierard LA; Scheen AJ
Rev Med Liege; 2015 Sep; 70(9):450-5. PubMed ID: 26638446
[TBL] [Abstract][Full Text] [Related]
6. Combination of ezetimibe and moderate-intensity statin for patients with atherosclerotic cardiovascular disease: a paradigm shift in lipid management landscape.
Pedicino D; Volpe M
Eur Heart J; 2022 Nov; 43(41):4227-4228. PubMed ID: 36101476
[No Abstract] [Full Text] [Related]
7. Does the addition of ezetimibe to statins reduce cardiovascular risk?
Araya FI; Grassi B
Medwave; 2016 Dec; 16(Suppl5):e6632. PubMed ID: 27922588
[TBL] [Abstract][Full Text] [Related]
8. [Statin intolerance].
Graversen CB; Larsen ML; Schmidt EB
Ugeskr Laeger; 2015 Aug; 177(36):. PubMed ID: 26324293
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness of the addition of ezetimibe to ongoing statin therapy in modifying lipid profiles and attaining low-density lipoprotein cholesterol goals in older and elderly patients: subanalyses of data from a randomized, double-blind, placebo-controlled trial.
Pearson T; Denke M; McBride P; Battisti WP; Brady WE; Palmisano J
Am J Geriatr Pharmacother; 2005 Dec; 3(4):218-28. PubMed ID: 16503317
[TBL] [Abstract][Full Text] [Related]
10. A Clinical Guide to Combination Lipid-Lowering Therapy.
Russell C; Sheth S; Jacoby D
Curr Atheroscler Rep; 2018 Mar; 20(4):19. PubMed ID: 29516190
[TBL] [Abstract][Full Text] [Related]
11. Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes.
Cannon CP; Blazing MA; Giugliano RP; McCagg A; White JA; Theroux P; Darius H; Lewis BS; Ophuis TO; Jukema JW; De Ferrari GM; Ruzyllo W; De Lucca P; Im K; Bohula EA; Reist C; Wiviott SD; Tershakovec AM; Musliner TA; Braunwald E; Califf RM;
N Engl J Med; 2015 Jun; 372(25):2387-97. PubMed ID: 26039521
[TBL] [Abstract][Full Text] [Related]
12. An updated review of lipid-modifying therapy.
Simons LA
Med J Aust; 2019 Jul; 211(2):87-92. PubMed ID: 31006138
[TBL] [Abstract][Full Text] [Related]
13. Statin plus ezetimibe treatment in clinical practice: the SI-SPECT (Slovenia (SI) Statin Plus Ezetimibe in Cholesterol Treatment) monitoring of clinical practice study.
Fras Z; Mikhailidis DP
Curr Med Res Opin; 2008 Sep; 24(9):2467-76. PubMed ID: 18655751
[TBL] [Abstract][Full Text] [Related]
14. A 10-year experience using combined lipid-lowering pharmacotherapy in children and adolescents.
Araujo MB; Pacce MS
J Pediatr Endocrinol Metab; 2016 Nov; 29(11):1285-1291. PubMed ID: 27718491
[TBL] [Abstract][Full Text] [Related]
15. Combination Lipid-Lowering Therapies for the Prevention of Recurrent Cardiovascular Events.
Lee S; Cannon CP
Curr Cardiol Rep; 2018 May; 20(7):55. PubMed ID: 29802475
[TBL] [Abstract][Full Text] [Related]
16. Strategies to overcome statin intolerance.
Agouridis AP; Nair DR; Mikhailidis DP
Expert Opin Drug Metab Toxicol; 2015 Jun; 11(6):851-5. PubMed ID: 25786568
[TBL] [Abstract][Full Text] [Related]
17. [Strengthened support for statin therapy as secondary prevention. Doubtful evidence for more intensive lowering of cholesterol levels].
Håkansson J
Lakartidningen; 2011 Jun 1-14; 108(22-23):1234-5. PubMed ID: 21786497
[No Abstract] [Full Text] [Related]
18. Effect of statins and non-statin LDL-lowering medications on cardiovascular outcomes in secondary prevention: a meta-analysis of randomized trials.
Koskinas KC; Siontis GCM; Piccolo R; Mavridis D; Räber L; Mach F; Windecker S
Eur Heart J; 2018 Apr; 39(14):1172-1180. PubMed ID: 29069377
[TBL] [Abstract][Full Text] [Related]
19. Statin intolerance and new lipid-lowering treatments.
Mesi O; Lin C; Ahmed H; Cho LS
Cleve Clin J Med; 2021 Jul; 88(7):381-387. PubMed ID: 34210712
[No Abstract] [Full Text] [Related]
20. Systematic review: comparative effectiveness and harms of combination therapy and monotherapy for dyslipidemia.
Sharma M; Ansari MT; Abou-Setta AM; Soares-Weiser K; Ooi TC; Sears M; Yazdi F; Tsertsvadze A; Moher D
Ann Intern Med; 2009 Nov; 151(9):622-30. PubMed ID: 19884623
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
